Regulus Therapeutics
RGLS
#7021
Rank
โ‚น51.77 B
Marketcap
โ‚น747.79
Share price
0.00%
Change (1 day)
468.39%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚น4.02 Billion

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚น4.24 Billion a decrease over its 2023 earnings that were of -โ‚น2.7 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น4.02 Billion-5.25%
2024 -โ‚น4.24 Billion56.97%
2023 -โ‚น2.7 Billion6.51%
2022 -โ‚น2.54 Billion2.53%
2021 -โ‚น2.47 Billion93.59%
2020 -โ‚น1.28 Billion-15.41%
2019 -โ‚น1.51 Billion-64.46%
2018 -โ‚น4.25 Billion-33.26%
2017 -โ‚น6.36 Billion-13.98%
2016 -โ‚น7.4 Billion44.77%
2015 -โ‚น5.11 Billion-1.63%
2014 -โ‚น5.2 Billion203.6%
2013 -โ‚น1.71 Billion8.65%
2012 -โ‚น1.58 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚น833.95 B-19,287.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น174.48 B-4,114.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น736.15 B-17,036.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น1.199 T-27,699.15%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น854.35 B-19,756.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚น10 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚น10.79 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น11.94 B-374.76%๐Ÿ‡บ๐Ÿ‡ธ USA